| Literature DB >> 32273131 |
Hamza Ben Yahia1, Nadia Boujelbene2, Wafa Babay1, Inès Ben Safta3, Sabrine Dhouioui1, Inès Zemni3, Mohamed Ali Ayadi3, Lamia Charfi4, Hadda Imene Ouzari1, Vera Rebmann5, Roberta Rizzo6, Karima Mrad2, Maha Driss4, Inès Zidi7.
Abstract
HLA-G has been widely implicated in advanced cancers through different pathways of immunosuppression allowing tumor escape. Contrarily, HLA-E has a controversial role in the tumor escape from the immune system. IDO catabolic enzyme is known to be up-regulated in many tumors types allowing their immune escape. Based on these considerations, we investigated the expression of HLA-G, HLA-E and IDO molecules in endometrial cancer (EC) and their association with prognostic clinicopathologic parameters. Their expression were checked in tumoral and adjacent endometrial tissues. Both HLA-G and IDO immunostaining were significantly increased in EC tissues compared to normal residual endometrial glands (Mann Whitney U-test, p = 0.0001 and p = 0,020 respectively). However, HLA-E was highly expressed in tumoral tissues as well as in normal residual endometrial glands (respectively, 100% and 81.8%). Increased HLA-G expression levels were observed in high histological grade (grade 3), and in the non-endometrioid type 2 EC. Unexpectedly, patients with IDO Low expression had significantly impaired overall survival compared to patients with IDO High (log-rank p = 0.021). Conversely, HLA-E low expression was associated to an improved overall survival EC (log-rank p = 0.004). We concluded that, HLA-G and IDO are highly expressed in EC compared to adjacent normal endometrial tissues, that might be interesting for the EC outcome.Entities:
Keywords: Endometrial cancer; HLA-E; HLA-G; IDO; Immunohistochemistry
Mesh:
Substances:
Year: 2020 PMID: 32273131 DOI: 10.1016/j.humimm.2020.03.008
Source DB: PubMed Journal: Hum Immunol ISSN: 0198-8859 Impact factor: 2.850